Sensimed

Executive Summary

Sensimed SA is a Swiss medical device company pioneering continuous glaucoma monitoring with its SENSIMED Triggerfish® smart contact lens. The device measures ocular dimensional changes over 24 hours, providing data to enable personalized treatment for glaucoma patients. Founded in 2003 and based in Lausanne, the company addresses a critical unmet need in ophthalmology: the lack of round-the-clock intraocular pressure (IOP) monitoring, which can reveal fluctuations missed during office visits. Triggerfish has received CE marking in Europe and is used in select clinics, but global adoption remains limited. The technology holds promise for improving glaucoma management by facilitating earlier detection of disease progression and optimizing therapy. However, commercialization challenges include reimbursement hurdles, competition from traditional IOP measurement devices, and the need for broader clinical validation to demonstrate improved patient outcomes. Sensimed's success hinges on securing strategic partnerships or licensing deals to accelerate market penetration and regulatory clearances in key regions such as the United States.

Upcoming Catalysts (preview)

• Q4 2026FDA Approval or 510(k) Clearance for Triggerfish in the U.S.40% success
• H1 2027Strategic Partnership or Licensing Deal with a Major Ophthalmology Company60% success
• Q3 2026Publication of Pivotal Clinical Study Data Demonstrating Improved Patient Outcomes70% success